Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
NK911 is a novel supramolecular nanocarrier designed for the enhanced delivery of doxorubicin (DXR) and is one of the successful polymer micelle systems to exhibit an efficient accumulation in solid tumours in mice. The purpose of this study was to define the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of NK911 and to evaluate its pharmacokinetic profile in man. NK911 was given intravenously to patients with solid tumours every 3 weeks using an infusion pump at a rate of 10 mg DXR equivalent min(-1). The starting dose was 6 mg DXR equivalent m(-2), and the dose was escalated according to the accelerated titration method. A total of 23 patients participated in this study. Neutropenia was the predominant haematological toxicity, and grade 3 or 4 neutropenia was observed at doses of 50 and 67 mg m(-2). Common nonhaematological toxicities were mild alopecia, stomatitis, and anorexia. In the dose identification part of the study, DLTs were observed at a dose of 67 mg m(-2) (grade 4 neutropenia lasting more than 5 days). Thus, this dosage level was determined to be the MTD. Infusion-related reactions were not observed in any cases. The C(5 min) and area under the concentration curve parameters of NK911 exhibited dose-dependent characteristics. Among the 23 patients, a partial response was obtained in one patient with metastatic pancreatic cancer. NK911 was well tolerated and produced only moderate nausea and vomiting at myelosuppressive dosages. The recommended phase II dose was determined to be 50 mg m(-2) every 3 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This same concept was used by Kataoka and colleagues in a series of works leading to development of polymeric micelle NK911, which was evaluated clinically [146, 147].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“These characteristics, which are unique to solid tumours, constitute the basis of the enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Maeda et al, 2000).”
BackgroundSelf-citationWHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211 · cited 2×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
BackgroundMuggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 647 · cited 2×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
BackgroundAccelerated Titration Designs for Phase I Clinical Trials in Oncology
Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 639 · cited 2×
“Dose escalation was performed according to the previously described accelerated titration method (Simon et al, 1997).”
MethodDevelopment of the polymer micelle carrier system for doxorubicin
Nakanishi, T., Fukushima, S., Okamoto, K., Suzuki, M., Matsumura, Y., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00341-8 · Cited by 570 · cited 7×
“The hydrophobic inner core enables NK911 to entrap a sufficient amount of DXR. NK911 has a diameter of about 40 nm (Nakanishi et al, 2001).”
BackgroundMethodSelf-citationUziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., & Gabizon, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1777 · Cited by 477 · cited 1×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
Background(1991) · PubMed · Cited by 418
Cited by
Items 401–500 of 621
Historical View of the Design and Development of Nanocarriers for Overcoming Biological Barriers
Alonso, M. J., & Couvreur, P. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849735292-00003 · Cited by 19
Platinum in Biomedical Applications
Sinitsyna, O. V., Paralikar, P., Pandit, R., & Rai, M. K. (2018) · Springer eBooks · doi:10.1007/978-3-319-74814-6_7 · Cited by 22
Managa, M., Ngoy, B. P., & Nyokong, T. (2017) · Journal of Photochemistry and Photobiology A Chemistry · doi:10.1016/j.jphotochem.2017.02.018 · Cited by 17
Ahmad, Z., Majeed, S., & Shah, A. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.09.016 · Cited by 16
Tang, H., Zhang, J., Tang, J. T., Shen, Y., Guo, W., Zhou, M., Wang, R., Jiang, N., Gan, Z., & Yu, Q. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00425 · Cited by 16
The Best Guess Approach to Phase I Trial Design
Rosa, D. D., Harris, J., & Jayson, G. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2006.02.4299 · Cited by 16
Soo, P. L., Dunne, M., Liu, J., & Allen, C. J. (2008) · Springer eBooks · doi:10.1007/978-0-387-77668-2_12 · Cited by 17
Block copolymer micelles as long-circulating drug vehicles
Patha, A. S., Patil, T., Pandey, P. K., Kuche, K., Ghadi, R., & Jain, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91248-8.00008-8 · Cited by 19
Nanoparticles as drug carriers
Patravale, V. B., Dandekar, P. P., & Jain, R. D. (2012) · Elsevier eBooks · doi:10.1533/9781908818195.29 · Cited by 17
Use of Nanostructured Polymer in the Delivery of Drugs for Cancer Therapy
Khan, M. J., Svedberg, A., Singh, A. A., Ansari, M. S., & Karim, Z. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816771-7.00013-2 · Cited by 21
Nanovectorization of Prostate Cancer Treatment Strategies: A New Approach to Improved Outcomes
Omabe, K. N., Paris, C., Lannes, F., Taïeb, D., & Rocchi, P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050591 · Cited by 17
Stimuli-Responsive Poly(aspartamide) Derivatives and Their Applications as Drug Carriers
Zhang, G., Yi, H., & Bao, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168817 · Cited by 17
“Besides NK105, poly(aspartic acid)-based polymers were also applied in two other formulations, NK911 [21] and NC-6300 [22,23].”
MethodLiu, Z., Wang, K., Wang, T., Wang, Y., & Ge, Y. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103523 · Cited by 15
Torchilin, V. P. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.30 · Cited by 16
Drug-Specific Design of Telodendrimer Architecture for Effective Doxorubicin Encapsulation
Jiang, W., Wang, X., Guo, D., Luo, J., & Nangia, S. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b06070 · Cited by 16
Targeting Triple Negative Breast Cancer with a Small-sized Paramagnetic Nanoparticle
Zhang, L., Varma, N. R. S., Zhang, G., Ewing, J. R., Arbab, A. S., & Ali, M. M. (2016) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000404 · Cited by 15
“For example, a micellar formulation of doxorubicin (NK911) has been evaluated and shown to reduce the in vivo incidence of toxicity, and to provide improved chemotherapeutic activity when compared to a simple solution formulation of doxorubicin [18,19].”
BackgroundSavić, R., Azzam, T., Eisenberg, A., Nedev, H. N., Rosenberg, L. C., & Maysinger, D. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.03.028 · Cited by 18
Ma, Q., Li, B., Yu, Y., Zhang, Y., Wu, Y., Ren, W., Zheng, Y., He, J. F., Xie, Y., Song, X., et al. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.01.046 · Cited by 14
Gao, S., Islam, R., & Fang, J. Q. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020136 · Cited by 16
“Otherwise, disruption of unstable nano-formulation in circulation wil result in si il r i molecular drugs [10,12,43].”
BackgroundBiodegradable polymeric micelles for drug delivery applications
Bölgen, N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-101997-9.00027-8 · Cited by 18
Cancer Therapy with Drug Delivery Systems
Wakaskar, R. R. (2017) · Journal of Pharmacogenomics & Pharmacoproteomics · doi:10.4172/2153-0645.100e158 · Cited by 13
“One of the classic examples in clinical trials is NK911, a block copolymer of PEG and polyaspartic acid and a bound doxorubicin fraction for metatstatic pancreatic cancer treatment [11].”
Drug Delivery Using Theranostics: An Overview of its Use, Advantages and Safety Assessment
Chiari‐Andréo, B. G., Abuçafy, M. P., Manaia, E. B., da Silva, B. L., Rissi, N. C., Oshiro, J. A., & Chiavacci, L. A. (2019) · Current Nanoscience · doi:10.2174/1573413715666190618162321 · Cited by 13
Development of stimuli-responsive intelligent polymer micelles for the delivery of doxorubicin
Yang, F., Xu, J., Fu, M., Ji, J., Chi, L., & Zhai, G. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1766474 · Cited by 15
Petrenko, V. A. (2011) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.s4-008 · Cited by 16
Balaure, P. C., & Grumezescu, A. M. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140304103437 · Cited by 13
Motloung, B. M., Babu, B., Prinsloo, E., & Nyokong, T. (2020) · Polyhedron · doi:10.1016/j.poly.2020.114683 · Cited by 15
Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review)
Volovăț, S. R., Negru, S. M., Stolniceanu, C. R., Volovat, C. D., Lungulescu, C. V., Scripcariu, D. V., Cobzeanu, B. M., Ştefănescu, C., Grigorescu, C., Augustin, I. G., et al. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9967 · Cited by 15
Mittal, A., & Chitkara, D. (2016) · Therapeutic Delivery · doi:10.4155/tde.15.90 · Cited by 14
Vasilakes, A. L., Dziubla, T. D., & Wattamwar, P. P. (2013) · Wiley eBooks · doi:10.1002/9781118747896.ch5 · Cited by 15
Acharya, A., Roy, N., Newaskar, V., Rai, A., Ghosh, A., Nagpure, M., Giri, S. K., Sahni, G., & Guchhait, S. K. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117611 · Cited by 13
Li, C., Zhang, Y., Li, M., Zhang, H., Zhu, Z., & Xue, Y. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103309 · Cited by 14
Szilágyi, B. Á., Gyarmati, B., Kiss, E. L., Budai-Szűcs, M., Misra, A. K., Csányi, E., László, K., & Szilágyi, A. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113254 · Cited by 13
Cytoplasm-Responsive Delivery Systems for siRNA Using Cell-Penetrating Peptide Nanomicelles
Okada, H., Ogawa, T., Tanaka, K., Kanazawa, T., & Takashima, Y. (2014) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(14)50001-9 · Cited by 12
Aminoglycoside-derived amphiphilic nanoparticles for molecular delivery
Miryala, B., Godeshala, S., Grandhi, T. S. P., Christensen, M. D., Tian, Y., & Rege, K. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.06.028 · Cited by 13
Nanotherapeutic Platforms for Cancer Treatment: From Preclinical Development to Clinical Application
Egusquiaguirre, S. P., Pedraz, J. L., Hernández, R. M., & Igartua, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-47347-7.00029-x · Cited by 14
Conventional Nanosized Drug Delivery Systems for Cancer Applications
Vergallo, C., Hafeez, M. N., Iannotta, D., Santos, H. A., d’Avanzo, N., Dini, L., Cilurzo, F., Fresta, M., Marzio, L. D., & Christian, C. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_1 · Cited by 15
Meena, P., & Kishore, N. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.116718 · Cited by 13
Kinoshita, R., Ishima, Y., Chuang, V. T. G., Watanabe, H., Shimizu, T., Ando, H., Okuhira, K., Otagiri, M., Ishida, T., & Maruyama, T. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081209 · Cited by 12
“Doxil®, a PEGylated liposome preparation for passive targeting aimed at reducing the side effects of DOX, and various DOX-loaded nano-drug delivery system (DDS) preparations [5,6], including the micellar preparation NK911, have been developed [7].”
BackgroundBiodistribution of polymer hydrogel capsules for the delivery of therapeutics
Hinton, T. M., Monaghan, P., Green, D., Kooijmans, S. A. A., Shi, S., Breheney, K., Tizard, M. L., Nicolazzo, J. A., Zelikin, A. N., & Wark, K. L. (2012) · Acta Biomaterialia · doi:10.1016/j.actbio.2012.05.028 · Cited by 13
Click Chemistry in Polymersome Technology
Saraiva, N. M., Alves, A. C., Costa, P. C., & Correia‐da‐Silva, M. (2024) · Pharmaceuticals · doi:10.3390/ph17060747 · Cited by 14
Makimoto, A., Fang, J. Q., & Maeda, H. (2021) · Cancers · doi:10.3390/cancers13153698 · Cited by 11
“In contrast, NK911, as described above, is rather unstable in the blood stream and released 50% of the APIs within two hours and 100% within 24 h [31,32].”
BackgroundChoudhury, H., Pandey, M., Saravanan, V., Mun, A. T. Y., Bhattamisra, S. K., Parikh, A. R., Garg, S., & Gorain, B. (2023) · Biomaterials Advances · doi:10.1016/j.bioadv.2023.213556 · Cited by 13
Layered Communication Protocol for Macro to Nano-Scale Communication Systems
Sharp, A., Raja, S. M., Wysocki, B. J., & Wysocki, T. A. (2010) · International Conference on Communications · doi:10.1109/icc.2010.5501831 · Cited by 11
Drug delivery applications of injectable biomaterials
Overstreet, D. J., von Recum, H. A., & Vernon, B. L. (2011) · Elsevier eBooks · doi:10.1533/9780857091376.2.95 · Cited by 12
Prasad, P., Molla, M. R., Cui, W., Canakci, M., Osborne, B. A., Mager, J., & Thayumanavan, S. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b00900 · Cited by 12
Sawdon, A. J., Zhang, J., Wang, X., & Peng, C. (2018) · Nanomaterials · doi:10.3390/nano8121041 · Cited by 12
Polymeric Drug Delivery Systems in Biomedicine
Gulyaev, I. A., Sokol, M. B., Mollaeva, M. R., Klimenko, M. A., Yabbarov, N. G., Chirkina, M., & Nikolskaya, E. D. (2025) · Biochemistry (Moscow) · doi:10.1134/s0006297924603976 · Cited by 13
Lipid Spheres as Attractive Nanoscale Drug Delivery Platforms for Cancer Therapy
Uckun, F. M. (2011) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000128 · Cited by 11
“One ABC drug delivery formulation made of polyethylene glycol and polypropylene glycol block copolymers (PEO-PPO-PEO) has been in clinical trial [26] whereas several new generation ABCs have either received regulatory approval or entered proof-of-principle clinical testing [27-31].”
BackgroundPeptide-directed delivery of drug-loaded nanocarriers targeting CD36 overexpressing cells
Zheng, Y., Fang, X., Yang, Y., & Wang, C. (2020) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2020.125970 · Cited by 10
Triple-negative breast cancer treatment meets nanoparticles: Current status and future direction
Shokooh, M. K., Emami, F., Duwa, R., Jeong, J., & Yook, S. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103274 · Cited by 11
Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Esposito, C., Crema, A., Ponzetto, A., Murtas, G., & Carloni, G. (2013) · Current Drug Metabolism · doi:10.2174/13892002113149990009 · Cited by 10
“DXR, aspartic acid PEG Phase I-III Gastroesophageal, Pancreatic [29,141]”
BackgroundMethodMultifunctional core–shell polymeric and hybrid nanoparticles as anticancer nanomedicines
Goračinova, K., Geškovski, N., Dimchevska, S., Li, X., & Gref, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813669-0.00004-x · Cited by 12
Advances in Polymer Micelles for Cancer Therapy: From Conventional to Smart Delivery Systems
Bryaskova, R. G., Staykov, K., & Ganchev, D. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18020177 · Cited by 11
Das, T., Mondal, S., Das, S., Das, S., & Saha, K. D. (2024) · Free Radical Research · doi:10.1080/10715762.2024.2360013 · Cited by 11
“…generated much more attention as biomaterials due to its excellent degradability, no toxicity, and mechanical strength and also approved by FDa [12]. the polymeric micelles as PlGa-PeG (PP) were structured as amphiphilic copolymers with hydrophobic core containing PlGa that serves as a…”
Reduction of Hepatotoxicity Induced by Doxorubicin
Bengaied, D., Ribeiro, A. J., Amri, M., Scherman, D., & Arnaud, P. (2017) · Journal of Integrative Oncology · doi:10.4172/2329-6771.1000193 · Cited by 8
Predicting the Loading Capability of mPEG‐PDLLA to Hydrophobic Drugs Using Solubility Parameters†
Sun, J., Wei, Q., Shen, N., Tang, Z., & Chen, X. (2020) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202000078 · Cited by 11
Taheri, A., Rad, A., Sadeghi, E., & Varshosaz, J. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200917145551 · Cited by 9
Kubicek, C. P. (2015) · Springer eBooks · doi:10.1007/978-3-319-22708-5_9 · Cited by 14
New short interfering RNA-based therapies for glomerulonephritis
Shimizu, H., & Fujita, T. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.61 · Cited by 10
POLYMERIC MICELLES: POTENTIAL DRUG DELIVERY DEVICES
Deepak, P., Nagaich, U., Sharma, A. K., Gulati, N., & Chaudhary, A. (2013) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.14499/indonesianjpharm0iss0pp222-237 · Cited by 21
“This polymeric micelle can efficiently entrap free Dox in the inner core, and the augmented preparation called NK911 which is now under a phase II clinical assessment (Matsumura et al., 2004).”
BackgroundAsakura, T., Yokoyama, M., SHIRAISHI, K., Aoki, K., & Ohkawa, K. (2018) · Anticancer Research · doi:10.21873/anticanres.12353 · Cited by 12
Mehata, A. K., Viswanadh, M. K., Solomon, V. R., & Muthu, M. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824476-0.00018-8 · Cited by 8
Micellar-Based Nanoparticles for Cancer Therapy and Bioimaging
Andrade, F., Almeida, A., Rafael, D. F. D. S., Schwartz, S., & Sarmento, B. F. C. C. (2018) · Nanomedicine and nanotoxicology · doi:10.1007/978-3-319-89878-0_6 · Cited by 9
Nanopharmacy: Exploratory Methods for Polymeric Materials
Bansal, K. K., Sasso, L., Makwana, H., Awwad, S., Brocchini, S., & Alexander, C. (2016) · Wiley eBooks · doi:10.1002/9783527800681.ch10 · Cited by 9
Andrade‐Gagnon, B., & Oh, J. K. (2024) · Polymer Chemistry · doi:10.1039/d4py00660g · Cited by 7
Encapsulation-based enhancements in modern drug delivery systems
Bakrim, S., Khalid, A., Abdalla, A. N., Ibrahim, S. E., Hamza, S. M. A., Omari, N. E., Wen, G. K., Lee, L., & Bouyahya, A. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126470 · Cited by 9
Alpinetin: anti-human gastric cancer potential and urease inhibition activity in vitro
Zhang, H., Jiang, Q., Gong, G., Li, M., & Alotaibi, S. H. (2021) · Archives of Medical Science · doi:10.5114/aoms/138832 · Cited by 8
Gharnas‐Ghamesh, H., Masoumi, M., & Moghadam, V. E. (2022) · Journal of Applied Polymer Science · doi:10.1002/app.52162 · Cited by 8
Nanotechnology in Cancer Therapy: Overview and Applications
Choi, E. J. (2011) · Journal of Pharmaceutical Investigation · doi:10.4333/kps.2011.41.2.059 · Cited by 7
“Doxil® is one of several nanoparticle formulations of doxorubicin that have been investigated clinically (Gabizon et al., 1994; Matsumura et al., 2004b; Heidel et al., 2011).”
BackgroundMethodInfluentialPolymeric nanoparticles for potential drug delivery applications in cancer
Fatima, S., Quadri, S. N., Parveen, S., Beg, S., Rahman, M., Ahmad, F. J., & Abdin, M. Z. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821095-6.00009-4 · Cited by 11
Assessment of Toxicity and Safety Profiles of Nanoparticles
(2020) · Letters in Applied NanoBioScience · doi:10.33263/lianbs101.18771888 · Cited by 9
Henn, J. G., Aguirre, T. A. S., Nugent, M., & Moura, D. J. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105254 · Cited by 11
Nanoformulations for Therapy of Pancreatic and Liver Cancers
de Souza, P. C., Ranjan, A., & Towner, R. A. (2015) · Nanomedicine · doi:10.2217/nnm.14.231 · Cited by 7
Enhanced Vascular Permeability in Solid Tumors: A Promise for Anticancer Nanomedicine
Taurin, S., & Greish, K. F. (2013) · Cancer metastasis · doi:10.1007/978-94-007-6028-8_4 · Cited by 11
Stealth Engineering for In Vivo Drug Delivery Systems
Mohapatra, A., Morshed, B. I., Haggard, W. O., & Smith, R. A. (2015) · Critical Reviews in Biomedical Engineering · doi:10.1615/critrevbiomedeng.2016016141 · Cited by 8
Theranostic Polymeric Micelles for Cancer Imaging and Therapy
Huang, G., Khemtong, C., Bey, E. A., Boothman, D. A., Sumer, B. D., & Gao, J. (2012) · Nanostructure science and technology · doi:10.1007/978-1-4614-2305-8_12 · Cited by 7
Micellization and Drug Solubility Enhancement Part II: Polymeric Micelles
Liu, R., Forrest, M. L., & Kwon, G. S. (2008) · CRC Press eBooks · doi:10.1201/9781420009552.ch13 · Cited by 9
Inertial migration of polymer micelles in a square microchannel
Shi, Q., Wu, J., Chen, H., Xu, X., Yang, Y., & Ding, M. (2024) · Soft Matter · doi:10.1039/d3sm01304a · Cited by 6
Current development of theragnostic nanoparticles for women’s cancer treatment
Kashyap, A., Kumari, M., Singh, A., Mukherjee, K., & Maity, D. (2024) · Biomedical Materials · doi:10.1088/1748-605x/ad3311 · Cited by 7
Pharmaceutical Nanotechnology: Overcoming Drug Delivery Challenges in Contemporary Medicine
Ganta, S., Singh, A., Coleman, T. P., Williams, D., & Amiji, M. M. (2014) · Nanostructure science and technology · doi:10.1007/978-1-4614-2140-5_10 · Cited by 11
Preclinical to Clinical Development of Nanomedicines
Svenson, S. (2014) · Frontiers in nanobiomedical research · doi:10.1142/9789814520652_0058 · Cited by 7
Dual Pseudo and Chemical Crosslinked Polymer Micelles for Effective Paclitaxel Delivery and Release
Song, X., Yuan, K., Li, H., Xu, S., & Li, Y. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00184 · Cited by 6
van Gaal, E. V. B., & Crommelin, D. J. A. (2015) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-16241-6_2 · Cited by 12
Hafezi, M., & Sharif, F. (2015) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2015.09.005 · Cited by 9
Antimicrobial Photodynamic Inactivation and Antitumor Photodynamic Therapy with Fullerenes
de Freitas, L. F., & Hamblin, M. R. (2016) · Morgan & Claypool Publishers eBooks · doi:10.1088/978-1-6817-4247-2 · Cited by 6
Nanocarriers in Drug and Gene Delivery
Pandita, D., Munjal, A., Godara, S., & Lather, V. (2018) · Springer eBooks · doi:10.1007/978-981-10-4702-2_6 · Cited by 6
Nonviral Gene Therapy: Peptiplexes
Tomich, J. M., Wessel, E., Choi, J., & Avila, L. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814470-1.00008-3 · Cited by 9
An Overview of Polymeric Nanoparticles as Potential Cancer Therapeutics
Agarwal, S. V., Dominic, A., & Wasnik, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816963-6.00002-9 · Cited by 9
Dong, W., Zhang, J., Zhuang, Z., Zhong, J., & Zhang, J. (2022) · Journal of Experimental Nanoscience · doi:10.1080/17458080.2022.2054995 · Cited by 6
The Significance of Nanoparticles in Medicine and Their Potential Application in Asthma
Tortorella, S. M., & Karagiannis, T. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0706-9_10 · Cited by 9
Implementation of Nanoparticles in Cancer Therapy
Bayır, E., Bilgi, E., & Şendemir, A. (2014) · Advances in chemical and materials engineering book series · doi:10.4018/978-1-4666-5824-0.ch018 · Cited by 5
Ahmad, Z., Arshad, N., Alsaab, H. O., Selamoğlu, Z., & Shah, A. (2024) · Polymer Bulletin · doi:10.1007/s00289-024-05413-8 · Cited by 5
Polymeric Micelles in Targeted Drug Delivery
Murthy, R. S. R. (2014) · Advances in delivery science and technology · doi:10.1007/978-3-319-11355-5_16 · Cited by 7
PEO-Modified Poly(L -Amino Acid) Micelles for Drug Delivery
Xiong, X.-B., Aliabadi, H. M., & Lavasanifar, A. (2006) · CRC Press eBooks · doi:10.1201/9781420006636-18 · Cited by 7
Sotoudegan, F., Amini, M., Faizi, M., & Aboofazeli, R. (2017) · Europe PMC (PubMed Central) · Cited by 5
Cellesi, F., & Tirelli, N. (2011) · Elsevier eBooks · doi:10.1533/9780857091376.3.298 · Cited by 6
Polymeric Micelles for Formulation of Anti-Cancer Drugs
Soo, P. L., Liu, J., Allen, C. J., Lee, H., & Butler, M. (2006) · CRC Press eBooks · doi:10.1201/9781420006636.sec4 · Cited by 6
Physico-chemical characterization and anti-laryngeal cancer effects of the gold nanoparticles
Jiang, M., Zhang, L., Li, L., & Khedri, M. R. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.104545 · Cited by 5
PEGylated polymer micelles for anticancer drug delivery carrier
Kamimura, M., & Nagasaki, Y. (2014) · Elsevier eBooks · doi:10.1016/b978-0-444-62614-1.00014-4 · Cited by 5
Multifunctional Nanoparticles for Cancer Theragnosis
Lee, S., Kwon, I. C., & Kim, K. (2011) · Wiley eBooks · doi:10.1002/9780470767047.ch22 · Cited by 5
Metadata
- Authors
- Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., & Watanabe, N.
- Affiliations
- National Cancer Center Hospital East (JP)
- National Cancer Center Hospital (JP)
- Nippon Kayaku (Japan) (JP)
- Corresponding author
- Matsumura, Y
- Venue
- British Journal of Cancer
- Published
- 2004-10-12
- Volume
- 91
- Issue
- 10
- Pages
- 1775-1781
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2410050
- OpenAlex
- W2056347214
- Cited by
- 623
- References
- 17
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 20 · 2023: 18 · 2022: 28 · 2021: 35 · 2020: 28 · 2019: 23 · 2018: 25 · 2017: 37 · 2016: 42 · 2015: 38 · 2014: 53 · 2013: 28 · 2012: 54
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- doxorubicin, polymeric micelles, supramolecular nanocarriers, maximum tolerated dose, dose-limiting toxicity, neutropenia, pharmacokinetics, solid tumors, metastatic pancreatic cancer, accelerated titration, recommended phase 2 dose, drug delivery
- MeSH terms
- Aged, Antineoplastic Agents, Doxorubicin, Drug Administration Schedule, Female, Humans, Male, Micelles, Middle Aged, Nausea, Neoplasms, Neutropenia, Peptides, Polyethylene Glycols, Vomiting, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.